Although number of patients choosing for Gilead Sciences Inc. (NASDAQ:GILD) [Detail Analytic Report] hepatitis C drugs HCV prissiest to rise in the US, pricing pressures are anticipated to have a negative impact on franchise’s incomes in 2016. Gilead Sciences experienced a in order surge in new patients opting for firm’s HCV drugs in the US in 1FIRST QUARTER6. However, there was a drop in incomes earned per patient. The decrease in incomes per patient was mainly attributed to the rise in price discounts given to payers as well as to shortened durations of therapy.
As recently India has reversed, course and granted authorization to Gilead Sciences Inc’s patent for its hepatitis C drug Sovaldi, marking a setback for patient groups who reported move could stop affordable copies of the drug. The drug was rejected for a patent by Indian patent authority in January 2015 on the basis it represented only minor changes to a previous formulation, and the firm already had licensing accords with manufacturers in India. Following an appeal by Gilead, the Indian Patent Office of New Delhi on Monday agreed its application for the drug saying it found its compounds to be “novel” and “inventive.”
ChemoCentryx, Inc. (NASDAQ:CCXI) [Detail Analytic Report] released that preclinical data using a series of orally-accessible inhibitors of chemokine receptor known as CCR6, have been designated for a poster presentation at the 2016 Society for Examinational Dermatology Yearly Meeting, being held May 11-14, 2016 in Scottsdale, Arizona.
Chief Medical Officer of ChemoCentryx, Pirow Bekker stated that in past several years, results from both preclinical models together with clinical experience have revealed that Th17 cells and their signature cytokine IL17 have a critical role in the pathogenesis of psoriasis. They and others have amassed data showing that Th17 cells are regulated by CCR6, and they before reported that CCX9664, a small molecule inhibitor of CCR6, cut skin inflammation in models of psoriasis, and reduced the number of IL17-secreting T cells in psoriatic skin. He added, “We and others have amassed data showing that Th17 cells are regulated by CCR6, and we before reported that CCX9664, a small molecule inhibitor of CCR6, reduced skin inflammation in models of psoriasis, and reduced the number of IL17-secreting T cells in psoriatic skin.
Prima Biomed Ltd. (NASDAQ:PBMD) [Detail Analytic Report]together with U.S.-based Sydys Corporation, Inc. released contract through which Sydys will license Prima’s CVac immuno-oncology program and oversee its future development. Marc Voigt, Prima’s CEO, commented that following extensive discussions with a number of third parties, they have reached what they consider to be an entrepreneurial solution which we believe best positions CVac for clinical success and, hopefully, commercialization.
Importantly, this alliance continues CVac program development without additional resource commitment from Prima, while providing the potential for considerable future milestone and royalty payments over time. The ongoing development will be contingent on additional successful capital raising for subsequent trials but we are confident that the Sydys team has the ability and connections in the US to undertake this program.